Researchers analyzed 20 existing studies to see if a blood test that looks for human papillomavirus (HPV) DNA could help with cervical cancer. The test checks for tiny pieces of HPV DNA circulating in the blood, known as cfDNA. The studies included people who already had HPV-positive cervical cancer. The goal was to understand if this blood test could accurately detect cancer and predict if it might come back after treatment.
The review found the test was very good at correctly identifying people who did not have cervical cancer, with a specificity of 96%. However, it only correctly identified cancer in about 47% of people who had it, meaning it missed many cases. For people who had been treated, a positive test result three months later was strongly associated with the cancer progressing or coming back sooner.
No safety issues with the test itself were reported in this analysis. The main reason to be careful is that this was not a new clinical trial, but a combined look at past studies. The test's ability to find all cancer cases was limited. Readers should understand this is a promising area of research for monitoring treatment, but the test is not yet a standard or perfect tool for initial cancer detection.